Concepedia

Steve Gendreau

SG

Statistics

Publications

2

Citations

75

H-Index

2

Active since

2010

Steve Gendreau is an author specializing in cancer pharmacology, dose-response modulation, and oncology pharmacotherapy.

Publications per year

2010–2010

2

Publications

2

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.

Irene Braña, P. LoRusso, José Baselga et al. · Journal of Clinical Oncology · 2010 · 51 citations

, , +9

A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

Richard B. Cohen, Pasi A. Jänne, J. A. Engelman et al. · Journal of Clinical Oncology · 2010 · 24 citations

, , +17

1–2 of 2